More about Krishna Institute of Medical Sciences Limited
Fundamentals for Krishna Institute of Medical Sciences Limited
Regulatory Filings for Krishna Institute of Medical Sciences Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Krishna Institute of Medical Sciences Limited
Business Operations:
Sector: HealthcareIndustry: Medical Care Facilities
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, Alzheimer's, bone, joint center specialties, and others. In addition, the company provides medical procedures for aneurysm, ankle arthritis and total ankle replacement, anterior cervical discectomy and fusion surgery, anterior resection, aortic aneurysm, aortic stent graft, aortic valve replacement, arthroscopy, atrial septal defect, bariatric surgery, and others. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Revenue projections:
With KIMS's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 52.071507 |
| debtToEquity | 123.719000 |
| earningsGrowth | -0.401000 |
| revenueGrowth | 0.292000 |
| grossMargins | 0.595950 |
| operatingMargins | 0.120480 |
| trailingEps | 7.480000 |
| forwardEps | 13.299020 |
KIMS's elevated forward PE ratio suggests limited upside potential and a risk of price correction. Investors must scrutinize this metric closely, ensuring it aligns with other fundamental indicators before making any decisions.
KIMS's high debt-to-equity ratio indicates a high level of leverage, meaning the company relies significantly on debt for financing. This can increase financial risk, particularly in times of economic instability or reduced profitability.
With both earnings and revenue growth in low territory, Krishna Institute of Medical Sciences Limited is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
Krishna Institute of Medical Sciences Limited's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
KIMS's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting KIMS to generate stronger earnings compared to the previous financial year.
Price projections:
Krishna Institute of Medical Sciences Limited's price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.
Recommendation changes over time:
Analysts' buy bias toward KIMS suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, KIMS is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction